Background and aim: Familial Pulmonary Fibrosis (FPF) is an emerging group of interstitial lung diseases (ILDs) caused by mutations mainly involving telomere-related genes (TRGs) and surfactant-related genes (SRGs). Although, in 2023, the European Respiratory Society (ERS) proposed a statement for FPF management, these still remain a burden. Our work aimed to evaluate the management and impact of FPF in three different Italian medical settings: university hospitals (UHs), non-university hospitals (n-UHs) and outpatient clinics. Methods: This survey was created by diffuse ILDs Study Group of Società Italiana di Pneumologia/ Italian Respiratory Society (SIP-IRS) and diffused via email to all SIP-IRS members. The descriptive statistical analysis was conducted through version 8.0 © 2023 GraphPad Software. Categorical variables were expressed as frequencies and percentages. Chi-square test was used to compare categorical variables. A p-value < 0.05 was regarded as significant. Results: Twenty participants replied to the survey, of which 65% (13/20) worked at UH while the remaining 25% (6/20) and 5% (1/20) worked at n-UH and outpatient clinics, respectively. Centers with, at least, 150 ILD patients visits/year followed a higher number of FPF patients, regardless of university affiliation (p=0.0046). Despite significant discrepancies in genetic testing and availability of counselling were registered, no statistically significant differences in patients’ anamnesis assessment were observed between UHs and n-UHs (p=0.4192 and p=0.6525). However, there were relevant differences in the number of FPF patients undergoing genetic assessment in the centers with genetics lab or unit inside the hospital (p=0.0253). There was no consensus regarding the impact of FPF diagnosis on lung transplantation and screening of asymptomatic relatives. Similarly, no differences were reported in antifibrotic prescriptions between UHs and n-UHs. Although the typical UIP pattern was the most common radiological pattern observed in FPF patients, there were no differences in the prevalence of histopathological patterns between UHs and n-UHs. Conclusions: Improving pulmonologists’ knowledge of the approach, diagnosis and management of FPF is a global medical topic. Scientific societies can provide significant support in raising physicians’ awareness of this issue.

THE MANAGEMENT OF FAMILIAL PULMONARY FIBROSIS IN DIFFERENT MEDICAL SETTINGS: WHERE DOES THAT LEAVE US? AN ITALIAN NATIONWIDE SURVEY

D'Alessandro M.;
2024-01-01

Abstract

Background and aim: Familial Pulmonary Fibrosis (FPF) is an emerging group of interstitial lung diseases (ILDs) caused by mutations mainly involving telomere-related genes (TRGs) and surfactant-related genes (SRGs). Although, in 2023, the European Respiratory Society (ERS) proposed a statement for FPF management, these still remain a burden. Our work aimed to evaluate the management and impact of FPF in three different Italian medical settings: university hospitals (UHs), non-university hospitals (n-UHs) and outpatient clinics. Methods: This survey was created by diffuse ILDs Study Group of Società Italiana di Pneumologia/ Italian Respiratory Society (SIP-IRS) and diffused via email to all SIP-IRS members. The descriptive statistical analysis was conducted through version 8.0 © 2023 GraphPad Software. Categorical variables were expressed as frequencies and percentages. Chi-square test was used to compare categorical variables. A p-value < 0.05 was regarded as significant. Results: Twenty participants replied to the survey, of which 65% (13/20) worked at UH while the remaining 25% (6/20) and 5% (1/20) worked at n-UH and outpatient clinics, respectively. Centers with, at least, 150 ILD patients visits/year followed a higher number of FPF patients, regardless of university affiliation (p=0.0046). Despite significant discrepancies in genetic testing and availability of counselling were registered, no statistically significant differences in patients’ anamnesis assessment were observed between UHs and n-UHs (p=0.4192 and p=0.6525). However, there were relevant differences in the number of FPF patients undergoing genetic assessment in the centers with genetics lab or unit inside the hospital (p=0.0253). There was no consensus regarding the impact of FPF diagnosis on lung transplantation and screening of asymptomatic relatives. Similarly, no differences were reported in antifibrotic prescriptions between UHs and n-UHs. Although the typical UIP pattern was the most common radiological pattern observed in FPF patients, there were no differences in the prevalence of histopathological patterns between UHs and n-UHs. Conclusions: Improving pulmonologists’ knowledge of the approach, diagnosis and management of FPF is a global medical topic. Scientific societies can provide significant support in raising physicians’ awareness of this issue.
2024
familial pulmonary fibrosis
genetic mutations
interstitial lung diseases
medical settings
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14085/56005
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 12
social impact